Passive Immune-oncology Therapy (New Antibody Drug)
OBI-888, is a Monoclonal Antibody that targets the Globo H antigen. The Phase I Dose-Escalation was completed in 2019. Subsequently, Phase II, Stage I, of the cohort Dose-Expansion study is currently being conducted at nine institutions, including the University of Texas MD Anderson Cancer Center and Taipei Veterans General Hospital. Current study focuses on patients with locally advanced or metastatic solid tumors. Tumor Globo H expression level is tested by an immunohistochemistry (IHC) method, approved by the FDA, as screening and recruitment criteria.
OBI-888 has been granted orphan drug designation (ODD) for pancreatic cancer.